NKY(SZ:300109)2022-10-24 16:00Financial Performance - Revenue for Q3 2022 reached ¥447,887,910.12, an increase of 36.11% year-over-year[4] - Net profit attributable to shareholders was ¥131,433,646.10, a significant increase of 691.46% compared to the same period last year[4] - Basic earnings per share for Q3 2022 was ¥0.40, reflecting a 700.00% increase year-over-year[4] - Revenue for Q3 2022 reached CNY 1,126,315,817.47, an increase of 30.14% compared to CNY 865,448,525.95 in the same period last year[9] - The company reported a net profit of CNY 825.05 million in retained earnings as of September 30, 2022, compared to CNY 723.99 million at the beginning of the year[24] - The net profit for the third quarter of 2022 was CNY 274,281,450.15, a significant increase from CNY 95,579,087.42 in the same period last year, representing a growth of approximately 187.5%[27] - The company reported a total comprehensive income of CNY 286,380,203.21 for the quarter, compared to CNY 94,447,928.79 in the previous year, marking an increase of approximately 203.5%[28] - Basic and diluted earnings per share were both CNY 0.85, compared to CNY 0.30 in the same quarter last year, representing a growth of 183.3%[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,818,965,076.53, a decrease of 4.28% from the end of the previous year[4] - The company’s total equity attributable to shareholders decreased by 2.19% to ¥3,336,856,641.97 compared to the end of the previous year[4] - The company's total assets as of September 30, 2022, amounted to CNY 3.82 billion, a decrease from CNY 3.99 billion at the beginning of the year[22] - The company's total liabilities decreased from CNY 589.76 million at the beginning of the year to CNY 492.20 million as of September 30, 2022[24] Cash Flow - Cash flow from operating activities for the year-to-date was ¥91,892,538.37, an increase of 84.83%[4] - Operating cash flow net amount was CNY 91,892,538.37, up 84.83% from CNY 49,717,011.30 year-on-year[10] - The net cash flow from operating activities was CNY 91,892,538.37, up from CNY 49,717,011.30 year-over-year, reflecting a growth of about 84.8%[31] - The company incurred total investment cash outflows of CNY 343,445,835.13, significantly higher than CNY 107,998,912.61 in the previous period, reflecting an increase of about 218.5%[31] - The financing activities resulted in a net cash outflow of CNY 417,695,215.03, compared to a net inflow of CNY 28,009,426.30 in the same period last year, indicating a shift in cash flow dynamics[31] Receivables and Inventory - Accounts receivable increased by 41.02% to ¥407,386,710.64, attributed to higher sales revenue[8] - The company reported a significant increase in inventory shares, rising by 189.01% to CNY 354,882,779.21, attributed to increased share buybacks[9] Tax and Other Income - The company’s income tax expense rose by 109.20% to CNY 79,245,889.16, reflecting increased profitability[10] - The company reported a tax expense of CNY 79,245,889.16, which is an increase from CNY 37,880,075.02 in the previous year, representing a growth of approximately 109.5%[27] - Other income increased by 72.23% to CNY 5,535,769.27, mainly due to government subsidies related to operations[9] - The company’s other comprehensive income after tax was CNY 12,098,753.06, compared to a loss of CNY 1,131,158.63 in the previous year, indicating a positive turnaround[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 18,726[12] - As of September 30, 2022, the company repurchased 16,292,525 shares through its dedicated repurchase account[13] - The top 10 unrestricted shareholders hold a total of 66,000,000 shares, with the largest shareholder holding 13,876,391 shares[13] - The company has a total of 64,482,403 restricted shares, with 8,701,999 shares released during the current period[16] - The company distributed cash dividends of 5.00 RMB per 10 shares, totaling 167,892,192.50 RMB[18] Future Plans and Investments - The company plans to establish a new subsidiary, "Xin Kaiyuan (Jiaozuo) Chemical Co., Ltd.," with an investment of CNY 100 million to build an integrated new energy industry project with an annual production capacity of 100,000 tons of NMP and 120,000 tons of BDO[20] - The total investment for the new project is estimated at CNY 1.35 billion, divided into two phases: the first phase (CNY 700 million) is expected to be completed between June 2023 and June 2024, while the second phase (CNY 650 million) is planned for completion between June 2025 and June 2026[20] - As of August 2022, the company has invested CNY 198.28 million in financial products using idle funds, with a maximum single investment of CNY 50 million and a total limit of CNY 200 million[21] Other Information - The company received the High-tech Enterprise Certificate, valid for three years from October 28, 2021[17] - The third quarter report of Boai New Open Source Medical Technology Group Co., Ltd. is unaudited[33]